A Phase 3 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor Triple CombinationTherapy in Cystic Fibrosis Subjects 2 Through 5 Years of Age
Details
Age
Child
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Principal Investigator
Jordana Hoppe, MD
Study ID
Protocol Number: 20-1827
More information available at ClinicalTrials.gov: NCT03525444
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers